Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Release: 4/30/19
Expiration: 4/30/20

Provided by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

This activity is supported by independent education grants from Biogen, EMD Serono, Genzyme, and Novartis.

Credit Available

Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™

Nurses — 1.0 contact hours (includes 1.0 pharmacology contact hours)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nursing professionals, PAs, and other healthcare professionals involved in the management of patients with MS.

Program Overview

This interactive enduring activity provides evidence-based education on the role of immune dysfunction in treatment and management considerations for patients living with multiple sclerosis (MS).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe regulation and dysregulation of the adaptive and the innate immune systems during development and progression of MS
  • Review the mechanisms of action of current and emerging immunotherapies for MS and their relevance to treatment decisions
  • Discuss immune-related toxicities of current and emerging immunotherapies used for MS
  • Utilize strategies to assess and manage immune-related toxicities
  • Evaluate relative risks and benefits of immunotherapeutic options
  • Employ patient-specific considerations when making treatment-sequencing decisions


Fred D. Lublin, MD

Director of the Corinne Goldsmith Dickinson

Center for Multiple Sclerosis at Mount Sinai Medical Center

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMSC designates this enduring activity for 1.0 contact hour of continuing nursing education credit (includes 1.0 pharmacology contact hours).

About Me

The Continuing Medical Education Program is an integral part of the organization’s overall mission which aims to improve learners’ competence and performance‐in‐practice and ultimately improve patient outcomes.

Related Posts